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Abstract
Introduction: The Orphan Drug Act encourages drug development for rare conditions. However, some orphan drugs
become top sellers for unclear reasons. We sought to evaluate the extent and cost of approved and unapproved uses of
orphan drugs with the highest unit sales.
Methods: We assessed prescription patterns for four top-selling orphan drugs: lidocaine patch (Lidoderm) approved for
post-herpetic neuralgia, modafinil (Provigil) approved for narcolepsy, cinacalcet (Sensipar) approved for hypercalcemia of
parathyroid carcinoma, and imatinib (Gleevec) approved for chronic myelogenous leukemia and gastrointestinal stromal
tumor. We pooled patient-specific diagnosis and prescription data from two large US state pharmaceutical benefit
programs for the elderly. We analyzed the number of new and total patients using each drug and patterns of
reimbursement for approved and unapproved uses. For lidocaine patch, we subcategorized approved prescriptions into
two subtypes of unapproved uses: neuropathic pain, for which some evidence of efficacy exists, and non-neuropathic pain.
Results: We found that prescriptions for lidocaine patch, modafinil, and cinacalcet associated with non-orphan diagnoses
rose at substantially higher rates (average monthly increases in number of patients of 14.6, 1.45, and 1.58) than prescriptions
associated with their orphan diagnoses (3.12, 0.24, and 0.03, respectively (p,0.001 for all)). By contrast, for imatinib,
approved uses increased significantly over off-label (0.97 vs. 0.47 patients, p,0.001). Spending on off-label uses was highest
for lidocaine patch and modafinil (.75%). Increases in lidocaine patch use for non-neuropathic pain far exceeded
neuropathic pain (10.2 vs. 3.6 patients, p,0.001).
Discussion: In our sample, three of four top-selling orphan drugs were used more commonly for non-orphan indications.
These orphan drugs treated common clinical symptoms (pain and fatigue) or laboratory abnormalities. We should continue
to monitor orphan drug use after approval to identify products that come to be widely used for non-FDA approved
indications, particularly those without adequate evidence of efficacy.
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Introduction
The Orphan Drug Act encourages the development of
medications to treat rare conditions. Manufacturers earn an
orphan designation by demonstrating to the Office of Orphan
Products Development (OOPD) at the Food and Drug Admin-
istration (FDA) that their product was directed at a disease
affecting fewer than 200,000 people in the US [1]. The Act
provides three primary incentives: 1) federal subsidies for clinical
trials; 2) a tax credit of 50% of clinical research costs; and 3) an
exclusive right to market the drug for seven years after approval.
The market exclusivity period is highly valuable, since it begins at
the time of approval, may run concurrently with—and even
extend past—a drug’s patent life [2], although unlike a patent, the
market exclusivity is limited to the approved indication. Orphan
designation also confers regulatory benefits, such as waiver of fees
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and Research (CDER) or the Center for Biologics Evaluation and
Research (CBER). In the past 25 years, over 350 products
designated as orphan drugs have subsequently been approved [3].
However, the Act has sparked some controversy [4–6]. Some
researchers have pointed to ‘‘blockbuster’’ orphans that annually
earn hundreds of millions, or billions, of dollars [7–8]. One
previous study of orphan drug approval in treatment of HIV
infection, for example, showed that manufacturers seek orphan
drug designation for treatment of AIDS, although the wider
community of HIV-infected patients used the drugs after approval,
leading to substantial revenues for the manufacturer [9]. Some
have questioned the appropriateness of providing additional
publicly funded incentives to manufacturers of orphan products
that become top sellers [10–11].
‘‘Blockbuster’’ orphans arise in two main ways: through wide
use of the orphan drugs outside their limited indications and
through high per-unit costs. Though the FDA approves drugs for
specific indications, physicians freely prescribe products for other
purposes or patient populations (‘‘off-label’’) [12]. Off-label use has
been reported in case studies of orphan drugs [13]. For example,
epoetin alfa (Epogen) was originally approved as an orphan
product in 1989 to treat anemia of end-stage renal disease, but was
soon used widely in other forms of anemia [14].
High revenues for orphan products may also result from per-
unit costs to patients or payers. The orphan drug imiglucerase
(Cerezyme), an enzyme replacement for patients with Gaucher’s
disease (which affects about 1,500 US patients), can cost over
$300,000 per patient per year [15]. High costs have been reported
across numerous orphan drugs [16–17].
To examine whether top-selling orphan drugs are characterized
by frequent off-label use or high costs (or both), we used a drug-
disease dataset of medication use and clinical diagnoses in a large
population of typical older patients. Our main hypothesis was that
we would find statistically significant off-label, non-orphan use of
these top-selling products.
Methods
Sources of data
We studied Medicare beneficiaries enrolled in 2 large state-
funded programs of medication coverage for older patients: the
Pharmaceutical Assistance Contract for the Elderly (PACE)
program in Pennsylvania and the Pharmaceutical Assistance for
the Aged and Disabled (PAAD) program in New Jersey from 1999
to 2005, when the introduction of Medicare Part D altered the
availability of prescription use data through these state-based
insurance programs. PACE and PAAD serve low-income adults
§65 years of age, providing generous pharmaceutical benefits for
virtually all prescription medications without restrictions, with a
consistently small co-payment. We chose these databases because
state programs, as well as the Medicare Part D program, are
grappling with high medication costs for their elderly enrollees.
During the study period, there were over 200,000 annual enrollees
in each program. We linked these paid prescription claim records
to Medicare Parts A and B claims data, which included
information on recorded diagnoses. Studies have documented
the positive predictive value of certain diagnoses (.94% for acute
myocardial infarction) and accuracy of diagnosis dates ($98%
specificity for cancer diagnoses) with these databases [18–19].
Study population
Participants were enrolled and active users of Medicare and
either prescription drug benefit program for at least 6 months
prior to their index date (defined below), as demonstrated by the
program eligibility files. Patients must have filled at least 1
prescription and have had at least 1 health care encounter
resulting in Medicare billing during this time period. The
Institutional Review Board of Brigham and Women’s Hospital
approved this study; because it was a study of de-identified,
already-collected data, the need to obtain informed consent was
waived.
Study drugs
The 100 top-selling pharmaceutical drugs by retail sales in 2009
included 12 approved for one or more orphan indications [20].
Among those products, 5 were targeted for orphan diseases at the
time of first FDA approval. We excluded the remaining 7, for
which the orphan indications were identified after the drug was
already on the market, because prescribing trends for these drugs
may be confounded by their market longevity before orphan
approval. Thus, the drugs in our sample were: lidocaine patch
(Lidoderm, Endo Pharmaceuticals, Chadds Ford PA), modafinil
(Provigil, Cephalon, Frazer PA), cinacalcet (Sensipar, Amgen,
Thousand Oaks CA), glatiramer (Copaxone, Teva, Petach Tikva,
Israel) and imatinib (Gleevec, Novartis, Basel, Switzerland). We
then excluded glatiramer because fewer than 50 patients who were
prescribed this drug met our eligibility criteria during the study
period. For the remaining four drugs, we used the FDA website to
identify their dates of approval for orphan indications, as well as
for any non-orphan indications [21]. The indications were linked
to the corresponding International Classification of Diseases,
Ninth Revision (ICD-9) diagnosis codes (Table 1). We obtained
disease prevalence estimates from the OOPD via a Freedom of
Information Act request. For cinacalcet, which is used in patients
with chronic kidney disease and two laboratory abnormalities
(hyperparathyroidism and hypercalcemia), we merged the main
study database with the records from the US Renal Data System
(USRDS), the national end-stage renal disease (ESRD) registry
[22]. This merger permitted us to accurately distinguish patients
with end-stage renal disease from patients with other chronic
kidney disease when determining on- and off-label uses of this
drug.
Identification and categorization of orphan drug
prescriptions
The index date was the first use of each study drug by an
enrollee in PAAD or PACE. After identifying filled prescriptions
for each drug, we divided uses into three mutually-exclusive
categories: ‘‘FDA-approved orphan use,’’ ‘‘FDA-approved non-
orphan use,’’ and ‘‘non-FDA approved use.’’ FDA-approved
orphan or non-orphan uses were defined as the presence of a
diagnosis code for approved orphan or non-orphan indications up
to 12 months before or 3 months after the index date. The
expanded time period enabled conservative estimates of off-label
use, given the rarity of orphan diagnosis codes. In the case of
imatinib, approved for a second orphan indication in 2002
(gastrointestinal stromal tumor, GIST), we assigned uses associated
with the supplemental orphan indication to the ‘‘FDA-approved
orphan use’’ category after February 2002. Non-FDA approved
uses were defined as all other uses. For each drug and category of
use, we recorded the monthly numbers of patients (new and total)
filling prescriptions and the total costs paid by the insurance
programs.
The exposure period ran from market authorization of the drug
to January 1, 2006, when Medicare Part D altered how enrollees
received prescription benefits through these state-based programs.
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unique restrictions on these products during the study period.
For each drug, we fit a linear regression model to estimate the
monthly increase in the number of patients on each drug, by
indication. The models for lidocaine patch included a spline term
with knot at May 2004, when PACE restricted access to this drug.
A spline term is a variable included as a predictor in a regression
model to allow the slope on a given predictor (the increase in
patients over time) to vary across regions of the predictor before
and after the ‘‘knot’’ – that is, the time point of interest [23]. The
models for modafinil included a spline term with knot at January
2004, when additional non-orphan indications were approved for
this drug. In each model, the intercept was fixed at zero, since the
number of filled prescriptions in month 0 (immediately before each
drug went on the market) is known to be zero.
Using these models, we estimated the monthly increase in the
number of patients on each drug by indication and time period.
Confidence intervals were computed using bootstrap resampling,
since the linear model assumption of independent, identically
distributed errors is likely false. We also used bootstrap resampling
to compute two-sided p-values to test the null hypothesis that the
monthly increase in unapproved users equaled the monthly increase
in approved orphan users in each time period. In addition, we
calculated the average number of new users taking each drug by
indication, where a new user was defined as a patient who had not
filled a prescription for the index drug in the prior 180 days [24].
Finally, we subdivided unapproved uses of lidocaine patch, the
most commonly prescribed drug in our sample, because some
evidence-based guidelines recommend its use as first-line therapy
for neuropathic pain apart from post-herpetic neuralgia [25–26],
which is by definition an off-label use. We identified patients with
diagnoses of neuropathic pain syndromes (excluding post-herpetic
neuralgia) up to 12 months before their index date. Among the
remaining patients, we noted those who received diagnoses of non-
neuropathic pain syndromes up to 12 months before their index
date. (See Appendix for a list of ICD-9 codes used to identify each
subclass of non-FDA approved prescriptions.) We recorded the
number of patients receiving at least one prescription and total
costs paid during each month.
National prescribing trends
The Centers for Medicare and Medicaid Services (CMS)
provide aggregated quarterly drug spending data from each state
Medicaid program [27]. We used this dataset to identify the total
amount paid for the four study drugs by each state Medicaid
program, including forty-nine states and the District of Columbia
(Arizona data were not available) during the study period.
Results
Off-label use of orphan drugs
Figures 1, 2, 3, and 4 present the total number of patients filling
prescriptions for each study drug by month and indication (trends
in new patients tracked these results (data not shown)). For
lidocaine patch, non-FDA approved uses far exceeded use by
patients with post-herpetic neuralgia (82.3% vs. 17.7%; see
Figure 1). The average monthly increase in use of lidocaine patch
for off-label uses was 14.6 patients (95% confidence interval [CI]:
13.3–15.8), compared to only 3.12 (95% CI: 3.01–3.22) for the
orphan use (p,0.001). In May 2004, the PACE program began to
require confirmation of on-label use from the prescribing
physician. Afterwards, off-label use in PACE dropped substantial-
ly; the subsequent rise (an average monthly increase of 35.3
patients (95% CI: 29.0–41.1)) reflects increasing use in PAAD
patients only, which had no such restriction.
Modafinil showed a similar pattern (Figure 2). A minority
(12.2%) of its use was for its on-label orphan indication
(narcolepsy), while 87.8% of its use was in patients who did not
have this diagnosis. The initial average monthly increase was 1.45
patients (95% CI: 1.35–1.54) for off-label uses, compared to only
0.24 (95% CI: 0.22–0.25) for the on-label use (p,0.001). Overall
utilization increased in the beginning of 2004, when modafinil was
approved for two supplemental non-orphan indications. However,
the average monthly increase in patients did not change
substantially for unapproved uses (2.56 (95% CI: 2.09–3.09)) or
orphan uses (0.31 (95% CI: 0.18–0.41)).
Evaluation of cinacalcet was limited to 2 years of experience
(Figure 3). For this drug, 1.2% of its use was for its approved
orphan indication of hypercalcemia and parathyroid carcinoma,
while 98.8% of use was for patients without these diagnoses
Table 1. Study drugs and FDA-approved indications (1998–2005).
Drug name
(brand name) FDA-Approved Indication
FDA Approval
Date
Orphan
Indication?
Estimated Orphan
Disease Prevalence
ICD-9
code(s)
Lidocaine patch
(Lidoderm)
Painful hypersensitivity and chronic
pain in postherpetic neuralgia
March 1999* Y 191,000 052, 053
Modafinil
(Provigil)
Excessive daytime sleepiness
in narcolepsy
December 1998 Y 120,000 347
Shift-work sleep disorder January 2004 N 327.36
Adjunctive treatment of
sleep apnea
January 2004 N 327.2, 780.57, 780.51,
780.53, 786.03
Cinacalcet
(Sensipar)
Hypercalcemia in patients
with parathyroid carcinoma
March 2004 Y 36,974 194.1, 237.4
Secondary hyperparathyroidism
in patients with chronic kidney
disease on dialysis
March 2004 N See USRDS
Imatinib
(Gleevec)
Chronic myelogenous
leukemia (CML)
May 2001 Y 42,000 205.1, 208.1, 758.89
Gastrointestinal stromal tumor (GIST) February 2002 Y 15,000 238.1, 238.9
*Lidocaine patch was not marketed by the manufacturer until September 1999.
USRDS=US Renal Data System (see reference 19).
doi:10.1371/journal.pone.0031894.t001
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unapproved indications). The average monthly increase in patients
for the FDA-approved orphan indication (hypercalcemia in
patients with parathyroid carcinoma) was 0.03 (95% CI: 0.01–
0.05). Use for the FDA-approved non-orphan indication (hyper-
parathyroidism in dialysis-dependent chronic kidney disease)
remained the predominant use of the product during the study
period (an average monthly increase of 5.48 patients (95% CI:
5.16–5.79) (p,0.001)), followed by unapproved uses (1.58 patients
(95% CI: 1.46–1.70) (p,0.001)).
Finally, for imatinib (Figure 4), prescriptions for the orphan
indications (61.3%) exceeded off-label use (38.7%). The average
monthly increase was 0.47 patients (95% CI: 0.45–0.49) for its off-
label uses vs. 0.97 patients (95% CI: 0.94–1.00) for its approved
orphan uses (p,0.001).
Costs of study drugs for public programs
Spending in PACE and PAAD for these products mirrored the
trends identified among the prescription data. Overall, total
spending for lidocaine patch was the greatest ($9.4 million), with
Figure 1. The number of patients filling prescriptions for lidocaine patch (Lidoderm) for on- and off-label uses in two state drug
benefit programs. Raw data are plotted over the linear regression line. Shaded regions indicate bootstrapped 95% confidence intervals for the
regression lines.
doi:10.1371/journal.pone.0031894.g001
Figure 2. The number of patients filling prescriptions for modafinil (Provigil) for on- and off-label uses in two state drug benefit
programs. Raw data are plotted over the linear regression line. Shaded regions indicate bootstrapped 95% confidence intervals for the regression
lines.
doi:10.1371/journal.pone.0031894.g002
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unapproved indications. For modafinil, the two programs paid
nearly $300,000 for approved uses, compared to more than $1
million for unapproved uses. For cinacalcet, approximately
$50,000 was spent for approved orphan use, $400,000 for the
approved non-orphan indication, and $130,000 for unapproved
uses. By contrast, a total of $5.3 million was spent on imatinib, of
which $3.6 million was for approved orphan uses and $1.7 million
for other uses.
At a national level, state Medicaid programs spent consider-
able sums on the orphan drugs studied: $370 million for
lidocaine patch (during 1999–2005), $156 million for modafinil
(1999–2005), $74 million for cinacalcet (2004–2005), and $162
million for imatinib (2001–2005). If our calculations for relative
on- and off-label expenditures are extrapolated to these national
figures, we estimated $495 million in spending on off-label uses
of these four orphan drugs by all state Medicaid programs
combined.
Figure 3. The number of patients filling prescriptions for cinacalcet (Sensipar) for on- and off-label uses in two state drug benefit
programs. Raw data are plotted over the linear regression line. Shaded regions indicate bootstrapped 95% confidence intervals for the regression
lines.
doi:10.1371/journal.pone.0031894.g003
Figure 4. The number of patients filling prescriptions for imatinib (Gleevec) for on- and off-label uses in two state drug benefit
programs. Raw data are plotted over the linear regression line. Shaded regions indicate bootstrapped 95% confidence intervals for the regression
lines.
doi:10.1371/journal.pone.0031894.g004
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Off-label use of lidocaine patch was dominated by patients with
diagnoses related to non-neuropathic pain. Initially, the observed
monthly increase in patients using lidocaine patch was 10.2
patients with non-neuropathic pain diagnoses (95% CI: 9.2–11.1)
and 3.6 patients with neuropathic pain diagnoses (95% CI: 3.2–
3.9) (p,0.001). PACE and PAAD paid nearly $1.8 million for uses
related to neuropathic pain, and $5.6 million for uses related to
non-neuropathic pain (the remaining $0.4 million could not be
classified in either category).
Discussion
We found far greater use of two products – lidocaine patch and
modafinil – for off-label indications than for any orphan
indications. Use of cinacalcet was dominated by its FDA-approved
non-orphan indication, but showed an increase in off-label use
during the study period. By contrast, imatinib use was mostly
related to its FDA-approved orphan indications. Thus, our
hypothesis was only partially correct – statistically significant
non-orphan and off-label use (compared to approved uses) was
found in three of the four drugs we studied. Among all four drugs,
we estimated that off-label use accounted for nearly $500 million
in Medicaid expenditures, with spending increasing substantially
during the exposure period.
The Orphan Drug Act has helped incentivize development of
new drugs for rare conditions, although this study shows that there
can be significant growth in off-label use of certain orphan drugs.
The lidocaine patch and modafinil were approved to treat
conditions manifested by common symptoms – respectively,
post-herpetic neuralgia (pain) and narcolepsy (daytime sleepiness)
– which can be intractable and frustrating conditions for both
doctor and patient [28–29]. Although their pre-approval studies
enrolled narrow populations covered by the Orphan Drug Act,
these drugs showed efficacy in managing such symptoms in one
context, so physicians may have been quick to prescribe them for
other patients with similar symptoms. Similarly, cinacalcet was
approved to treat laboratory abnormalities (hypercalcemia and
hyperparathyroidism) found outside the populations for which it
was originally approved. Unlike the other three drugs studied,
imatinib was approved for distinct conditions (CML and GIST).
Perhaps as a result, physicians were less likely to consider using
these drugs off-label.
The growth of these drugs into top-sellers may be explained by
other factors as well. Patients who present with chronic symptoms,
such as pain or fatigue, may learn about newly approved products
through media accounts and request prescriptions from their
physicians. Some use of medications for non-FDA approved
conditions has been illegally promoted by manufacturers; in the
case of modafinil, for example, the manufacturer settled a lawsuit
in 2008 for $425 million regarding alleged active promotion of its
product for use outside of narcolepsy [30].
Growth of total sales of imatinib was not associated with off-
label use, so could have been due to other factors, such as increases
in the unit cost (approximately $56,000 per course/patient/year
for GIST in 2009) [31]. Changes in unit costs also contributed to
increases in spending on the study drugs. Despite the substantial
commitment of resources through the Orphan Drug Act and other
government funding to assist in the development of orphan drugs,
their cost remains an important policy issue. For example, in 2009,
84% of Medicare Part D beneficiaries were enrolled in plans that
put imatinib in a specialty tier with co-insurance rates as high as
$1,366 per month [32]. Enacting limited waivers from state and
federal antitrust laws could allow insurance plans to voluntarily
band together in negotiating groups to seek lower drug prices for
expensive orphan drugs where no alternative therapies exist [33].
Another way to reduce rates of unapproved non-evidence-based
used of orphan drugs would be to vary the cost of the drug based
on the indication. For example, payers could charge low co-pays to
patients prescribed the drug to treat their orphan condition, and
correspondingly high co-pays for non-evidence-based use. Apply-
ing such value-based insurance design to promote more appro-
priate use of orphan drugs, however, is limited by payers’ ability to
distinguish among the reasons that drugs are prescribed. As a
result, orphan drugs are commonly priced the same for all
indications. Some payers have tried to use administrative pre-
certification forms for this purpose, although pharmaceutical
companies selling orphan drugs have been investigated for
allegedly teaching physicians how to fill out these forms to ensure
approval of the drug for off-label uses [34].
This study has certain limitations. We studied top-selling drugs,
so our conclusions do not generalize to all orphan-designated
products. We also determined FDA-approved and non-approved
uses from diagnosis codes submitted with billing claims from
health care encounters. It is possible that some of the patients we
identified as receiving a drug for unapproved indications may have
had the indicated disease, but did not have a recorded diagnosis of
it. Finally, the study population used to identify trends in
utilization and spending comprised elderly persons with complete
drug coverage residing in two states, and low-income patients in
the Medicaid program. Our results may differ from other
recipients of these agents.
In this analysis, we primarily focused on off-label use, rather
than evidence-based use. However, for one of the products, the
lidocaine patch, we found that an overwhelming share of the
prescriptions were for patients with diagnoses for non-neuropathic
pain syndromes, where no rigorous clinical trial evidence supports
its use. Off-label use can have solid supporting evidence, and may
be appropriate even in circumstances where gathering of
supporting evidence can be difficult [35]. On the other hand,
when non-FDA approved uses are not supported by adequate
clinical evidence, patients do not receive the intended benefits
from the drug, are less likely to be prescribed more effective
treatments, and are exposed to risks of adverse events with no
demonstrated countervailing benefits. The substantial costs of
orphan products to Medicaid add to the concern about off-label
and non-evidence-based uses. For the drugs in our sample, greater
attention to implementing value-based insurance design may help
limit non-evidence-based off-label use [36].
These findings documenting off-label use in certain top-selling
orphan drugs may have important implications for the Orphan
Drug Act and for drug development policy. Currently, generous
orphan drug incentives in the US are earned during drug
development or at the point of FDA approval, before the product
reaches the market. The Orphan Drug Act has proven useful in
encouraging the government and pharmaceutical manufacturers
to devote resources towards developing new drugs for orphan
conditions. Our data suggest that it might be preferable to
continue to monitor orphan drug use after approval to identify
products that come to be widely used for non-FDA approved
indications – especially those for which there is also inadequate
evidence of efficacy. Orphan drugs that quickly find widespread
use are likely to provide an adequate return on investment to their
manufacturers in a short time frame. When such use occurs
widely, it may be reasonable to terminate the orphan drug market
exclusivity period. The European version of the Orphan Drug Act
contains a ‘‘clawback’’ provision that permits reduction of the
statutory exclusivity period if the product is deemed sufficiently
Top-Selling Orphan Drugs
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and substantial revenues made by some orphan drug manufac-
turers in Europe [13]. Another alternative would be to seek
reimbursement of the considerable government investments made
in orphan drug development on the expectation that these drugs
would find only limited use. The concept of reimbursing initial
public investment in drug development remains controversial,
although it has recently been endorsed by Francis Collins, Director
of the National Institutes of Health [37].
Finally, our study suggests that regulators may be able to take a
more proactive step and predict certain orphan products that are
likely to be widely prescribed for non-FDA approved indications –
those initially designed and approved to treat common symptoms
or laboratory abnormalities, albeit in the context of a rare disease.
For these products, it may be reasonable to withhold orphan drug
status, and instead direct the limited resources of the program to
encouraging development of novel products (such as imatinib)
aimed at treating truly rare diseases. Applying incentives
selectively to developing such products would adhere more closely
to the original goals of the Orphan Drug Act.
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